Zydus Lifesciences to acquire India, Sri Lanka rights for Agenus cancer immunotherapy BOT/BAL
Ahmedabad: Zydus Lifesciences Limited has announced that it has entered into a definitive agreement with Agenus Inc. to acquire India and Sri Lanka commercial rights for its investigational Botensilimab (BOT) and Balstilimab (BAL), combination therapy.
Agenus Inc. is a clinical-stage immuno-oncology company developing immune therapies that effectively combat cancer. Agenus’ lead programme comprising Botensilimab (BOT) and Balstilimab (BAL), is a nextgeneration immunotherapy platform designed to strengthen and sustain the immune system’s response against tumour cells.
Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings.
As a part of the agreement, Zydus will be responsible for clinical development and regulatory approvals of licensed products in these territories and will pay 5% royalty on net sales upon successful approval & commercialization.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.